news
Celyad posts an update on its NKR-2 Trial
30 March 2016 | By Victoria White
Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...
List view / Grid view
Myeloma
news
Daratumumab and atezolizumab to be evaluated in two studies
22 March 2016 | By Victoria White
The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer...
news
Celgene’s Imnovid and Abraxane recommended for use in Ireland
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
news
Amgen’s Kyprolis launches in the UK for relapsed multiple myeloma
12 February 2016 | By Victoria White
Kyprolis (carfilzomib) is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma...
news
CHMP adopts positive opinion of Empliciti in multiple myeloma
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
news
Broad Institute Genomic Services offers genomic insight into Ninlaro
25 January 2016 | By Victoria White
Ninlaro (ixazomib) was recently approved by the FDA, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
news
FDA approves new Kyprolis combination therapy in multiple myeloma
22 January 2016 | By Victoria White
The FDA has approved the supplemental New Drug Application (sNDA) of Amgen’s Kyprolis (carfilzomib) for injection in combination with dexamethasone or with lenalidomide plus dexamethasone...
news
Takeda’s Ninlaro capsules now available in the US
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
news
Amgen presents new data on Kyprolis in multiple myeloma
7 December 2015 | By Victoria White
The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone...
news
FDA approves Empliciti for the treatment of multiple myeloma
1 December 2015 | By Victoria White
Empliciti (elotuzumab) has been approved as combination therapy with Revlimid (lenalidomide) and dexamethasone (ERd) in patients who have received one to three prior therapies.
news
FDA approves Ninlaro for multiple myeloma
23 November 2015 | By Victoria White
Ninlaro (ixazomib) is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
news
EC grants marketing authorisation to Kyprolis in multiple myeloma
20 November 2015 | By Victoria White
The announcement makes Kyprolis (carfilzomib) the first irreversible proteasome inhibitor approved in the EU for use in combination treatment of patients with relapsed multiple myeloma.
news
FDA approves Darzalex for multiple myeloma
17 November 2015 | By Victoria White
Darzalex (daratumumab) is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world...
news
Global multiple myeloma treatment market value to rise to $22.4b by 2023
29 October 2015 | By Victoria White
The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData...
news
Asia-Pacific multiple myeloma treatment market value to hit $2.8b by 2021
20 October 2015 | By Victoria White
The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021...
